Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
复制标题
DOI:
10.1371/journal.pone.0111481
复制
发表时间:
2014
期刊:
影响因子:
3.7
通讯作者:
Tsuda H
中科院分区:
文献类型:
--
作者:
Fukamachi K;Iigo M;Hagiwara Y;Shibata K;Futakuchi M;Alexander DB;Hino O;Suzui M;Tsuda H
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage. We have established transgenic rats carrying a mutated K-ras gene controlled by Cre/loxP activation. The animals develop PDA which is histopathologically similar to that in humans. Previously, we reported that serum levels of N-ERC/mesothelin were significantly higher in rats bearing PDA than in controls. In the present study, to determine whether serum levels of N-ERC/mesothelin correlated with tumor size, we measured N-ERC/mesothelin levels in rats bearing PDA. Increased serum levels of N-ERC/mesothelin correlated with increased tumor size. This result indicates an interrelationship between the serum level of N-ERC/mesothelin and tumor size. We next investigated the effect of chemotherapy on serum N-ERC/mesothelin levels. Rat pancreatic cancer cells were implanted subcutaneously into the flank of NOD-SCID mice. In the mice treated with 200 mg/kg gemcitabine, tumor weight and the serum level of N-ERC/mesothelin were significantly decreased compared to controls. These results suggest that serum N-ERC/mesothelin measurements might be useful for monitoring response to therapy.
登录
查看更多内容
影响因子:
3.6
作者:
HINO, O;KOBAYASHI, E;MITANI, H
通讯作者:
MITANI, H
影响因子:
11.5
作者:
Onda, Masanori;Nagata, Satoshi;Pastan, Ira
通讯作者:
Pastan, Ira
影响因子:
11.5
作者:
Shiomi, Kazu;Hagiwara, Yoshiaki;Hino, Okio
通讯作者:
Hino, Okio
影响因子:
4.8
作者:
KOJIMA, T;OHEDA, M;YAMAGUCHI, N
通讯作者:
YAMAGUCHI, N
DOI:
10.1016/j.bbrc.2009.10.019
发表时间:
2009-12-18
影响因子:
3.1
作者:
Fukamachi, Katsumi;Tanaka, Hajime;Tsuda, Hiroyuki
通讯作者:
Tsuda, Hiroyuki